Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 0.76 |
| ▸ | ABL1 | P00519 | 18/20 | 0.76 |
| ▸ | ABL2 | P42684 | 18/20 | 0.76 |
| ▸ | SRC | P12931 | 17/20 | 0.76 |
| ▸ | LCK | P06239 | 3/20 | 0.70 |
| ▸ | LYN | P07948 | 1/20 | 0.56 |
| ▸ | BTK | Q06187 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8107232 | 0.90 | ABL1 (0.78) | EGFRABL1ABL2SRCLCK | |
| SCHEMBL8098888 | 0.90 | SRC (0.65) | EGFRABL1ABL2SRCLCK | |
| SCHEMBL8107889 | 0.87 | SRC (0.64) | EGFRABL1ABL2SRCLCK | |
| SCHEMBL7022376 | 0.86 | ABL1 (0.69) | EGFRABL1ABL2SRCLCK | |
| SCHEMBL7021384 | 0.86 | EGFR (1.00) | EGFRABL1ABL2SRCLCK | |
| SCHEMBL8107295 | 0.86 | EGFR (0.86) | EGFRABL1ABL2SRCLCK | |
| SCHEMBL7015214 | 0.85 | ABL1 (0.79) | EGFRABL1ABL2SRCLCK | |
| SCHEMBL8108575 | 0.85 | SRC (0.71) | EGFRABL1ABL2SRCLCK | |
| SCHEMBL7019170 | 0.85 | EGFR (0.79) | EGFRABL1ABL2SRCLCK | |
| SCHEMBL8114099 | 0.85 | ABL1 (0.73) | EGFRABL1ABL2SRCLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0888353-B1 | N-7-HETEROCYCLYL PYRROLO [2,3-d]PYRIMIDINES AND THEIR USE | NOVARTIS AG (CH) | 2003-07-09 | — | — | EP | disclosed |
| US-6051577-A | TYROSINE INHIBITORS; BONE DISORDERS | NOVARTIS AG (CH) | 2000-04-18 | — | — | US | disclosed |